TWI630207B - 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 - Google Patents
作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 Download PDFInfo
- Publication number
- TWI630207B TWI630207B TW105120803A TW105120803A TWI630207B TW I630207 B TWI630207 B TW I630207B TW 105120803 A TW105120803 A TW 105120803A TW 105120803 A TW105120803 A TW 105120803A TW I630207 B TWI630207 B TW I630207B
- Authority
- TW
- Taiwan
- Prior art keywords
- pyrrolo
- alkyl
- group
- methyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74990505P | 2005-12-13 | 2005-12-13 | |
| US60/749,905 | 2005-12-13 | ||
| US81023106P | 2006-06-02 | 2006-06-02 | |
| US60/810,231 | 2006-06-02 | ||
| US85062506P | 2006-10-10 | 2006-10-10 | |
| US60/850,625 | 2006-10-10 | ||
| US85687206P | 2006-11-03 | 2006-11-03 | |
| US60/856,872 | 2006-11-03 | ||
| US85940406P | 2006-11-16 | 2006-11-16 | |
| US60/859,404 | 2006-11-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201704235A TW201704235A (zh) | 2017-02-01 |
| TWI630207B true TWI630207B (zh) | 2018-07-21 |
Family
ID=37903501
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105120803A TWI630207B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| TW095146502A TWI410407B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| TW107113620A TWI664182B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并[2,3-b]吡啶及吡咯并[2,3-b]嘧啶 |
| TW103117669A TW201434835A (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| TW103136068A TWI553008B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并[2,3-b]吡啶及吡咯并[2,3-b]嘧啶 |
| TW101121442A TWI468162B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095146502A TWI410407B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| TW107113620A TWI664182B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并[2,3-b]吡啶及吡咯并[2,3-b]嘧啶 |
| TW103117669A TW201434835A (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| TW103136068A TWI553008B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并[2,3-b]吡啶及吡咯并[2,3-b]嘧啶 |
| TW101121442A TWI468162B (zh) | 2005-12-13 | 2006-12-12 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
Country Status (36)
Families Citing this family (440)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| CN101263140A (zh) * | 2005-09-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 作为葡萄糖激酶活化剂的杂双环化合物 |
| JP5119154B2 (ja) * | 2005-09-22 | 2013-01-16 | インサイト・コーポレイション | Ｊａｎｕｓキナーゼの四環系阻害剤 |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| NZ567851A (en) * | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| TWI630207B (zh) | 2005-12-13 | 2018-07-21 | 英塞特控股公司 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| MX2008008320A (es) * | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Inhibidores de azaindol de aurora cinasas. |
| TWI382984B (zh) * | 2006-04-03 | 2013-01-21 | Astellas Pharma Inc | 雜環化合物 |
| CN101460499A (zh) * | 2006-04-05 | 2009-06-17 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的去氮杂嘌呤 |
| EP2446903B1 (en) | 2006-11-20 | 2019-10-09 | President and Fellows of Harvard College | Compositions for treating itch |
| EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| JP2010531850A (ja) * | 2007-07-02 | 2010-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| WO2009032338A1 (en) * | 2007-09-09 | 2009-03-12 | University Of Florida Research Foundation | Apratoxin therapeutic agents: mechanism and methods of treatment |
| WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| JP2011500806A (ja) * | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| ES2569528T3 (es) * | 2007-11-16 | 2016-05-11 | Incyte Holdings Corporation | 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus |
| CN101981036B (zh) * | 2008-02-06 | 2013-09-04 | 诺瓦提斯公司 | 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途 |
| WO2009114552A1 (en) * | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| PL2288610T3 (pl) * | 2008-03-11 | 2017-12-29 | Incyte Holdings Corporation | Azetydynowe i cyklobutanowe pochodne jako inhibitory jak |
| JP2011518221A (ja) * | 2008-04-21 | 2011-06-23 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｊａｎｕｓキナーゼの阻害剤 |
| US8871753B2 (en) * | 2008-04-24 | 2014-10-28 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8344144B2 (en) * | 2008-06-18 | 2013-01-01 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| RU2560153C2 (ru) * | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолпиридиновые соединения, ингибирующие jak, и способы |
| AU2009259867A1 (en) * | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| TWI665200B (zh) * | 2009-01-15 | 2019-07-11 | 英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| WO2010085597A1 (en) * | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| EP3643312A1 (en) | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| CN102459267B (zh) | 2009-06-08 | 2014-11-26 | 武田药品工业株式会社 | 用作jak抑制剂的二氢吡咯并萘啶酮化合物 |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| US20120172429A1 (en) | 2009-07-10 | 2012-07-05 | Woolf Clifford J | Permanently charged sodium and calcium channel blockers as anti- inflammatory agents |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| RU2538204C2 (ru) | 2009-09-10 | 2015-01-10 | Ф.Хоффманн-Ля Рош Аг | Ингибиторы jak |
| CA2782797C (en) | 2009-10-02 | 2018-08-07 | Avexxin As | Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles |
| CN105541847B (zh) * | 2009-10-09 | 2019-08-16 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
| US8389728B2 (en) * | 2009-11-06 | 2013-03-05 | The Arizona Board Of Regents | Pollen tube stimulants from Arabidopsis pistils |
| CN102844317B (zh) * | 2010-02-18 | 2015-06-03 | 因西特公司 | 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物 |
| WO2011109217A2 (en) * | 2010-03-02 | 2011-09-09 | Immunodiagnostics, Inc. | Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors |
| AU2015205858B2 (en) * | 2010-03-10 | 2017-04-13 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EP3050882B1 (en) * | 2010-03-10 | 2018-01-31 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PH12012502046A1 (en) * | 2010-04-14 | 2017-07-26 | Array Biopharma Inc | 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| SG10201503983QA (en) * | 2010-05-21 | 2015-06-29 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
| MX2013001970A (es) | 2010-08-20 | 2013-08-09 | Hutchison Medipharma Ltd | Compuestos de pirrolopirimidina y usos de los mismos. |
| WO2012040527A2 (en) * | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| AU2011320565A1 (en) | 2010-10-28 | 2013-05-23 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| CN103415515B (zh) * | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
| EP2651930B1 (en) * | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| JP5681819B2 (ja) | 2011-02-11 | 2015-03-11 | バットマーク・リミテッド | 吸入器コンポーネント |
| ES2547916T3 (es) * | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| MX2013009456A (es) * | 2011-02-24 | 2013-12-12 | Univ Hawaii | Compuestos de azufre aromaticos sustituidos y metodos para su uso. |
| EP2688890B1 (en) | 2011-03-22 | 2017-08-30 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| AU2012255792A1 (en) * | 2011-05-17 | 2013-11-07 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| US20140113919A1 (en) | 2011-06-14 | 2014-04-24 | Novartis Ag | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| WO2013008095A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| HK1198579A1 (en) | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| KR102030609B1 (ko) | 2011-09-02 | 2019-10-11 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AU2012313094B2 (en) * | 2011-09-22 | 2017-02-02 | Intervet International B.V. | Pyrazole carboxamides as janus kinase inhibitors |
| AU2012323399A1 (en) * | 2011-10-12 | 2014-05-29 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| EP2788000B1 (en) * | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| ES2867048T3 (es) * | 2012-06-15 | 2021-10-20 | Concert Pharmaceuticals Inc | Derivados deuterados de ruxolitinib |
| CA2880896C (en) | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CA2879603A1 (en) * | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| WO2014019908A2 (en) | 2012-08-02 | 2014-02-06 | Nerviano Medical Sciences S.R.L. | Substituted pyrroles active as kinases inhibitors |
| EP2897962A1 (en) | 2012-09-21 | 2015-07-29 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| MX2015002975A (es) * | 2012-10-26 | 2015-06-22 | Hoffmann La Roche | Inhibidores de la tirosina cinasa de bruton. |
| AU2013337824B2 (en) | 2012-11-01 | 2018-03-08 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| PL2919766T3 (pl) * | 2012-11-15 | 2021-10-04 | Incyte Holdings Corporation | Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| CA2892606A1 (en) * | 2012-12-06 | 2014-06-12 | Baruch S. Blumberg Institute | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| JP6371312B2 (ja) | 2013-01-29 | 2018-08-08 | アヴェクシン エーエス | 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物 |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| US20150380681A1 (en) * | 2013-02-12 | 2015-12-31 | Konica Minolta, Inc. | Organic electroluminescent element and lighting device |
| CN105189509B (zh) | 2013-03-06 | 2017-12-19 | 因赛特公司 | 用于制备jak抑制剂的方法及中间体 |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| SMT202100040T1 (it) | 2013-05-17 | 2021-03-15 | Incyte Corp | Derivati di bipirazolo come inibitori di jak |
| SG10201912203XA (en) | 2013-08-07 | 2020-02-27 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| EP3035966A1 (en) | 2013-08-20 | 2016-06-29 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP3057972A4 (en) * | 2013-10-15 | 2017-03-22 | V Jin | Novel compositions, uses and methods for their preparation |
| MX2016006894A (es) | 2013-11-27 | 2016-08-17 | Novartis Ag | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. |
| WO2015083028A1 (en) | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| KR102261733B1 (ko) * | 2013-12-18 | 2021-06-04 | 콘서트 파마슈티컬즈, 인크. | 룩소리티닙의 중수소화된 유도체 |
| CN110229159B (zh) * | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| CA2940659C (en) * | 2014-02-28 | 2023-01-03 | Incyte Corporation | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| EP4019518A1 (en) | 2014-02-28 | 2022-06-29 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| KR20240153401A (ko) | 2014-04-08 | 2024-10-22 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료 |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| RU2564891C1 (ru) * | 2014-05-27 | 2015-10-10 | Александр Александрович Кролевец | Способ получения нанокапсул цитокининов |
| US10363260B2 (en) * | 2014-05-28 | 2019-07-30 | Oncotracker, Inc. | Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| AU2015289929A1 (en) * | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| EP3179991B1 (en) | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
| SI3179992T1 (sl) | 2014-08-11 | 2022-09-30 | Acerta Pharma B.V. | Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1 |
| AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
| EP4578865A3 (en) | 2014-08-12 | 2025-07-30 | Monash University | Lymph directing prodrugs |
| EP3183252B1 (en) * | 2014-08-21 | 2021-05-12 | ratiopharm GmbH | Oxalate salt of ruxolitinib |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| CN105524067A (zh) * | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| WO2016063294A2 (en) * | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
| RS61853B1 (sr) | 2014-10-29 | 2021-06-30 | Bicyclerd Ltd | Biciklični peptidni ligandi specifični za mt1-mmp |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
| DK3831833T3 (da) | 2015-02-27 | 2022-11-14 | Incyte Holdings Corp | Fremgangsmåder til fremstillingen af en pi3k-inhibitor |
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| CA2979215A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| KR101859170B1 (ko) * | 2015-04-17 | 2018-05-17 | 광주과학기술원 | 트리아졸 화합물 및 이의 용도 |
| ES2734048T3 (es) * | 2015-04-29 | 2019-12-04 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidores de Janus cinasas (JAK) |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| US11021443B2 (en) | 2015-08-03 | 2021-06-01 | President And Fellows Of Harvard College | Charged ion channel blockers and methods for use |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| WO2017035366A1 (en) * | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| JP6802263B2 (ja) | 2015-09-02 | 2020-12-16 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| JP7118888B2 (ja) | 2015-09-08 | 2022-08-16 | モナッシュ ユニバーシティ | リンパ指向性プロドラッグ |
| WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| EP4086259A1 (en) | 2015-11-06 | 2022-11-09 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| ES2908470T3 (es) | 2015-11-09 | 2022-04-29 | Scherer Technologies Llc R P | Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| EP3389664A4 (en) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
| WO2017101777A1 (zh) * | 2015-12-15 | 2017-06-22 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物的盐 |
| KR20180094977A (ko) | 2015-12-17 | 2018-08-24 | 노파르티스 아게 | c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도 |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| CN108699063B (zh) * | 2015-12-31 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 一种芦可替尼的合成工艺 |
| JP7011600B2 (ja) | 2016-01-12 | 2022-01-26 | ジェイムズ リチャード ベレンソン， | 被験体の免疫状態をモニタリングするための改善された方法 |
| CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
| WO2017129116A1 (zh) * | 2016-01-26 | 2017-08-03 | 杭州华东医药集团新药研究院有限公司 | 吡咯嘧啶五元氮杂环衍生物及其应用 |
| CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
| EP4234552A3 (en) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| PL3884939T3 (pl) | 2016-03-09 | 2024-02-26 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| AU2017241524B2 (en) | 2016-03-28 | 2021-07-08 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| HRP20241345T1 (hr) | 2016-05-04 | 2024-12-20 | Sun Pharmaceutical Industries, Inc. | Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak |
| RU2743170C2 (ru) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных |
| CN107513069A (zh) * | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
| CN107759600A (zh) | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
| CN107513067A (zh) | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| CN113135920A (zh) | 2016-06-30 | 2021-07-20 | 株式会社大熊制药 | 吡唑并嘧啶衍生物作为激酶抑制剂 |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US11414413B2 (en) | 2016-07-26 | 2022-08-16 | Suzhou Longbiotech Pharmaceuticals Co., Ltd. | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof |
| SG11201901197PA (en) | 2016-08-24 | 2019-03-28 | Arqule Inc | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| IT201600092051A1 (it) * | 2016-09-13 | 2018-03-13 | Alessandro Antonelli | Composto medicale per il trattamento di tumori della tiroide |
| CN115448916A (zh) | 2016-10-14 | 2022-12-09 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| WO2018089499A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
| US11730819B2 (en) | 2016-12-23 | 2023-08-22 | Bicycletx Limited | Peptide derivatives having novel linkage structures |
| WO2018127699A1 (en) | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
| EA039352B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение |
| CA3055209A1 (en) | 2017-03-08 | 2018-09-13 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors, uses, and methods for production thereof |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| EP3615550A1 (en) | 2017-04-27 | 2020-03-04 | BicycleTx Limited | Bicyclic peptide ligands and uses thereof |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| BR112019024509A2 (pt) | 2017-05-23 | 2020-06-23 | Theravance Biopharma R&D Ip, Llc | Glicuronídeo de pró-fármacos dos inibidores da janus quinase |
| WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| CN107298680A (zh) * | 2017-07-12 | 2017-10-27 | 海门华祥医药科技有限公司 | 一种4‑氯‑7‑氮杂吲哚的生产工艺 |
| JP7216705B2 (ja) | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用方法 |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| US20200283482A1 (en) | 2017-08-14 | 2020-09-10 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| EP3675838A4 (en) | 2017-08-29 | 2021-04-21 | PureTech LYT, Inc. | LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| TWI821200B (zh) | 2017-09-27 | 2023-11-11 | 美商英塞特公司 | Tam抑制劑之鹽 |
| CN109651424B (zh) * | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
| US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
| BR112020008850A2 (pt) | 2017-11-03 | 2020-10-20 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 |
| KR102034538B1 (ko) | 2017-11-28 | 2019-10-21 | 주식회사한국파마 | Jak 저해제 화합물, 및 이의 제조방법 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| WO2019126378A1 (en) | 2017-12-19 | 2019-06-27 | Ariya Therapeutics, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR20200115620A (ko) | 2018-01-29 | 2020-10-07 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| JP7229257B2 (ja) | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| EP3746429B1 (en) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| KR102830476B1 (ko) | 2018-02-16 | 2025-07-08 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
| KR20200128518A (ko) | 2018-02-23 | 2020-11-13 | 바이사이클티엑스 리미티드 | 다량체성 비사이클릭 펩타이드 리간드 |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| US10696663B2 (en) | 2018-02-27 | 2020-06-30 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of TCR-NCK interaction |
| KR20210003086A (ko) | 2018-03-08 | 2021-01-11 | 노파르티스 아게 | 항-p-셀렉틴 항체의 용도 |
| CN110357887B (zh) * | 2018-03-26 | 2022-09-16 | 武汉誉祥医药科技有限公司 | 取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| EP3775284A1 (en) | 2018-03-30 | 2021-02-17 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| PT3773593T (pt) | 2018-03-30 | 2024-06-25 | Incyte Corp | Tratamento da hidradenite supurativa com inibidores de jak |
| SG11202010092XA (en) | 2018-04-13 | 2020-11-27 | Incyte Corp | Biomarkers for graft-versus-host disease |
| ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
| EP4043460B1 (en) | 2018-04-24 | 2024-06-05 | Merck Patent GmbH | Antiproliferation compounds and uses thereof |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN119258070A (zh) | 2018-06-01 | 2025-01-07 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| EP3805219A4 (en) | 2018-06-06 | 2022-03-23 | Gengle Therapeutics, Inc. | PYRAZOLOPYRIMIDI DERIVATIVE, ITS USE AND PHARMACEUTICAL COMPOSITION |
| BR112020025283A2 (pt) | 2018-06-15 | 2021-03-09 | Navitor Pharmaceuticals, Inc. | Análogos de rapamicina e usos dos mesmos |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
| JP6830460B2 (ja) * | 2018-07-05 | 2021-02-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| CN112823005B (zh) | 2018-08-10 | 2024-08-20 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| US11414431B2 (en) | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| CN112955459A (zh) | 2018-10-23 | 2021-06-11 | 拜斯科技术开发有限公司 | 双环肽配体和其用途 |
| CA3117336A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1 |
| IL282643B2 (en) | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| CA3120866A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN109394768B (zh) * | 2018-12-10 | 2019-08-23 | 牡丹江医学院 | 一种治疗湿疹的药物及其制备方法 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN113474045A (zh) | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | Pd-l1特异性的双环肽配体 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US11174264B2 (en) | 2019-01-23 | 2021-11-16 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| CN111620873B (zh) * | 2019-02-28 | 2021-12-28 | 沈阳药科大学 | 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途 |
| IL285999B2 (en) | 2019-03-05 | 2026-01-01 | Incyte Corp | JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP7692834B2 (ja) | 2019-03-11 | 2025-06-16 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| CA3129111A1 (en) | 2019-03-11 | 2020-09-17 | Bridget M. Cole | Charged ion channel blockers and methods for use |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| MA55320A (fr) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| AU2020253990A1 (en) | 2019-04-02 | 2021-10-28 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| JP2022527114A (ja) | 2019-04-05 | 2022-05-30 | カイメラ セラピューティクス， インコーポレイテッド | 分解剤およびそれらの使用 |
| AU2020262100B2 (en) | 2019-04-24 | 2023-03-16 | Elanco Us Inc. | A 7H-pyrrolo[2,3-d]pyrimidine JAK-inhibitor |
| KR20220004726A (ko) | 2019-05-02 | 2022-01-11 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | Jak 억제제로서의 치환된 피롤로피리딘 |
| KR102286372B1 (ko) | 2019-05-27 | 2021-08-05 | 주식회사한국파마 | Jak 저해제 화합물, 및 이를 포함하는 의약 조성물 |
| CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
| JP7592029B2 (ja) * | 2019-05-28 | 2024-11-29 | マンカインド ファーマ リミテッド | ヤヌスキナーゼ１の阻害のための新規化合物 |
| TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
| WO2020252012A1 (en) | 2019-06-10 | 2020-12-17 | Incyte Corporation | Topical treatment of vitiligo by a jak inhibitor |
| US12521438B2 (en) | 2019-06-10 | 2026-01-13 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| BR112021026382A2 (pt) | 2019-06-27 | 2022-02-08 | Crispr Therapeutics Ag | Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer |
| MX2021015995A (es) | 2019-06-28 | 2022-03-11 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2021022178A1 (en) * | 2019-07-31 | 2021-02-04 | Aclaris Therapeutics, Inc. | Substituted sulfonamide pyrrolopyridines as jak inhibitors |
| US20220251097A1 (en) * | 2019-08-01 | 2022-08-11 | St. Jude Childrens's Research Hospital | Molecules and methods related to treatment of uncontrolled cellular proliferation |
| JP2022548594A (ja) | 2019-09-11 | 2022-11-21 | ビンシア・バイオサイエンシーズ・インコーポレイテッド | Ｕｓｐ３０阻害剤及びその使用 |
| CN119874700A (zh) | 2019-09-13 | 2025-04-25 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| US20220306737A1 (en) | 2019-09-16 | 2022-09-29 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| EP4031139A1 (en) | 2019-09-16 | 2022-07-27 | Novartis AG | Use of an mdm2 inhibitor for the treatment of myelofibrosis |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CN110538183B (zh) * | 2019-10-09 | 2021-05-04 | 吉林大学 | 一种预防和治疗小儿湿疹的组合物及其制备方法 |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| JP2022551649A (ja) | 2019-10-10 | 2022-12-12 | インサイト・コーポレイション | 移植片対宿主病のバイオマーカー |
| JP7518900B2 (ja) | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| IL292612A (en) | 2019-11-01 | 2022-07-01 | Navitor Pharm Inc | Treatment methods using mtorc1 modulator |
| US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN114828845A (zh) | 2019-11-06 | 2022-07-29 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| JP7717065B2 (ja) | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法 |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN115052627A (zh) | 2019-12-17 | 2022-09-13 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| US12569485B2 (en) | 2019-12-23 | 2026-03-10 | Kymera Therapeutics, Inc. | SMARCA inhibitors and uses thereof |
| US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CA3166908A1 (en) | 2020-02-05 | 2021-08-12 | Daniel Kenneth BONNER | Lipid prodrugs of neurosteroids |
| CN111728975A (zh) * | 2020-02-25 | 2020-10-02 | 广东省检迅检测科技有限公司 | 用于减少运动损伤和促进运动损伤修复的组合物 |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| EP4114401A1 (en) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| EP4118070A4 (en) | 2020-03-11 | 2024-04-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CA3177830A1 (en) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| CN115836065B (zh) | 2020-06-02 | 2025-07-01 | 因赛特公司 | 制备jak1抑制剂的方法 |
| FI4161528T3 (fi) | 2020-06-03 | 2025-12-12 | Incyte Corp | Ruksolitinibin ja incb057643:n yhdistelmä käytettäväksi myeloproliferatiivisten kasvainten hoidossa |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| BR112022024729A2 (pt) | 2020-06-05 | 2023-02-28 | Kinnate Biopharma Inc | Inibidores de quinases do receptor do fator de crescimento de fibroblastos |
| WO2021260657A1 (en) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| KR20230074119A (ko) | 2020-08-03 | 2023-05-26 | 바이사이클티엑스 리미티드 | 펩타이드 기반 링커 |
| US11751108B2 (en) * | 2020-08-05 | 2023-09-05 | Qualcomm Incorporated | Execution of reduced signaling handover |
| WO2022036030A1 (en) * | 2020-08-12 | 2022-02-17 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| EP4196792A1 (en) | 2020-08-17 | 2023-06-21 | BicycleTX Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
| US11897889B2 (en) | 2020-08-18 | 2024-02-13 | Incyte Corporation | Process and intermediates for preparing a JAK1 inhibitor |
| WO2022040180A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
| AU2021344164A1 (en) * | 2020-09-16 | 2023-05-04 | Axceso Biopharma Co.,Ltd. | Pyrimidopyrimidinone compound and pharmaceutical composition comprising same |
| WO2022061351A1 (en) | 2020-09-16 | 2022-03-24 | Incyte Corporation | Topical treatment of vitiligo |
| EP4221711A1 (en) | 2020-10-02 | 2023-08-09 | Incyte Corporation | Topical ruxolitinib for treating lichen planus |
| EP4225317A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
| WO2022074599A1 (en) | 2020-10-08 | 2022-04-14 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
| EP4232425A4 (en) | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| CN114437079B (zh) * | 2020-10-30 | 2024-11-01 | 杭州邦顺制药有限公司 | 吡咯嘧啶五元氮杂环化合物的晶型 |
| KR102551758B1 (ko) | 2020-11-30 | 2023-07-05 | 주식회사한국파마 | 신규한 jak 특이 저해제 화합물, 및 이의 제조방법 |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN117015531A (zh) | 2020-12-02 | 2023-11-07 | 医肯纳肿瘤学公司 | Tead抑制剂及其用途 |
| TW202237125A (zh) | 2020-12-04 | 2022-10-01 | 美商英塞特公司 | 用於治療皮膚疾病之jak抑制劑與維生素d類似物 |
| AU2021396231A1 (en) | 2020-12-08 | 2023-06-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| JP2023554665A (ja) | 2020-12-18 | 2023-12-28 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用 |
| CA3202360A1 (en) | 2020-12-30 | 2022-07-07 | Nello Mainolfi | Irak degraders and uses thereof |
| MX2023008141A (es) | 2021-01-11 | 2023-10-20 | Incyte Corp | Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock). |
| WO2022165530A1 (en) * | 2021-02-01 | 2022-08-04 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| CN117098757A (zh) | 2021-02-02 | 2023-11-21 | 里米诺生物科学有限公司 | Gpr84拮抗剂和其用途 |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| US12252488B2 (en) | 2021-02-12 | 2025-03-18 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| US11773103B2 (en) | 2021-02-15 | 2023-10-03 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| CA3207049A1 (en) | 2021-02-15 | 2022-08-18 | Jared Gollob | Irak4 degraders and uses thereof |
| KR20230148208A (ko) | 2021-02-25 | 2023-10-24 | 임팩트 바이오메디신스, 인코포레이티드 | 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도 |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| US12325697B2 (en) | 2021-04-09 | 2025-06-10 | Nimbus Clio, Inc. | CBL-B modulators and uses thereof |
| KR20230172548A (ko) | 2021-04-16 | 2023-12-22 | 이케나 온콜로지, 인코포레이티드 | Mek 억제제 및 이의 용도 |
| SI4333840T1 (sl) | 2021-05-03 | 2026-01-30 | Incyte Corporation | Zaviralci poti jak1 za zdravljenje pruriga nodularisa |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| AU2022328272A1 (en) | 2021-08-11 | 2024-02-22 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| CN118019739A (zh) | 2021-08-25 | 2024-05-10 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
| KR102718345B1 (ko) * | 2021-09-16 | 2024-10-17 | 광주과학기술원 | 신규한 트리아졸릴피롤로피리미딘 유도체 및 이의 용도 |
| CA3231996A1 (en) * | 2021-09-18 | 2023-03-23 | Satya Srinivas HANUMARA | An improved process for the preparation of ruxolitinib phosphate |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| US12290565B2 (en) | 2021-11-17 | 2025-05-06 | Altrubio Inc. | Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers |
| WO2023102559A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN114044777B (zh) * | 2022-01-10 | 2022-04-19 | 南京佰麦生物技术有限公司 | 一种磷酸芦可替尼的制备方法 |
| US12091411B2 (en) | 2022-01-31 | 2024-09-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN114456181A (zh) * | 2022-02-21 | 2022-05-10 | 浙江乐普药业股份有限公司 | 一种芦可替尼的制备方法 |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
| EP4540252A1 (en) * | 2022-06-14 | 2025-04-23 | Incyte Corporation | Solid forms of a jak inhibitor and process of preparing the same |
| CN117384163B (zh) * | 2022-07-05 | 2026-02-17 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种含偕二氟基的化合物及其制备方法和用途 |
| CN119894873A (zh) | 2022-08-02 | 2025-04-25 | 里米诺生物科学有限公司 | 芳基三唑基和相关gpr84拮抗剂及其用途 |
| EP4565568A1 (en) | 2022-08-02 | 2025-06-11 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| KR20250056924A (ko) | 2022-08-02 | 2025-04-28 | 리미널 바이오사이언시스 리미티드 | 치환된 피리돈 gpr84 길항제 및 이의 용도 |
| WO2024028193A1 (en) | 2022-08-03 | 2024-02-08 | Medichem, S.A. | Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate |
| WO2024042448A1 (en) * | 2022-08-22 | 2024-02-29 | Granules India Limited | An improved process for the preparation of ruxolitinib |
| WO2024099396A1 (zh) * | 2022-11-11 | 2024-05-16 | 浙江奥翔药业股份有限公司 | 芦可替尼晶体及其药物组合物 |
| WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2024184926A1 (en) * | 2023-03-08 | 2024-09-12 | Aarti Pharmalabs Limited | Process for preparation of chiral ruxolitinib and salts thereof |
| WO2024187415A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| WO2024187416A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| US20240398810A1 (en) | 2023-05-21 | 2024-12-05 | Incyte Corporation | Topical ruxolitinib foam |
| CN120379669A (zh) | 2023-06-23 | 2025-07-25 | 凯麦拉医疗公司 | Irak降解剂及其用途 |
| EP4491175A1 (en) | 2023-07-10 | 2025-01-15 | Genepharm S.A. | A solid oral composition of ruxolitinib |
| EP4540253A4 (en) | 2023-09-04 | 2025-11-05 | Granules India Ltd | IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB AND A NEW CRYSTALLINE FORM THEREIN |
| IT202300018879A1 (it) | 2023-09-14 | 2025-03-14 | Chemelectiva S R L | Processo enzimatico per la preparazione di (r)-3-(4-bromo-1h-pirazol-1-il)-3- ciclopentilpropanenitrile, quale intermedio nella sintesi di ruxolitinib |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| US12364699B2 (en) | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| WO2025117642A1 (en) | 2023-12-01 | 2025-06-05 | Incyte Corporation | Ruxolitinib for treating hidradenitis suppurativa (hs) |
| EP4621803A1 (en) | 2024-03-22 | 2025-09-24 | Assistance Publique - Hôpitaux de Paris | Method for identifying patients in need for ici-induced myotoxicity treatment |
| TW202547468A (zh) * | 2024-03-27 | 2025-12-16 | 美商基利科學股份有限公司 | Ｓｔａｔ６之小分子調節劑 |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
| KR20260035991A (ko) | 2024-08-26 | 2026-03-13 | 인사이트 코포레이션 | 룩소리티닙의 약학적으로 허용 가능한 염의 국소 피부 제형 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| TWI553008B (zh) * | 2005-12-13 | 2016-10-11 | 英塞特控股公司 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并[2,3-b]吡啶及吡咯并[2,3-b]嘧啶 |
Family Cites Families (309)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) * | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| US3632836A (en) | 1968-10-25 | 1972-01-04 | Dow Chemical Co | Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides |
| US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| DE3220113A1 (de) * | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) * | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4404335A (en) | 1982-08-16 | 1983-09-13 | The Dow Chemical Company | Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) * | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
| US4921947A (en) | 1986-03-31 | 1990-05-01 | Eli Lilly And Company | Process for preparing macrolide derivatives |
| JPH0710876Y2 (ja) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | スクリュープレスにおける脱水筒の洗浄装置 |
| ATE139232T1 (de) * | 1989-10-11 | 1996-06-15 | Teijin Ltd | Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung |
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| IT1258781B (it) * | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| JPH0710876A (ja) * | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| USH1439H (en) | 1993-10-18 | 1995-05-02 | The Dow Chemical Company | Method to increase the level of α-glycol in liquid epoxy resin |
| EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
| US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| EP0836602B1 (en) | 1995-07-05 | 2002-01-30 | E.I. Du Pont De Nemours And Company | Fungicidal pyrimidinones |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5630943A (en) * | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| CA2250232A1 (en) | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
| JP2000513711A (ja) | 1996-04-18 | 2000-10-17 | メルク エンド カンパニー インコーポレーテッド | 癌の治療法 |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
| US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| CA2286239A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
| US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
| US5919779A (en) * | 1997-08-11 | 1999-07-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-Heteroaryl-dipyrido(2,3-B:3', 2'-F) azepines and their use in the prevention or treatment of HIV infection |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
| TW505646B (en) | 1998-06-19 | 2002-10-11 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds |
| WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| WO2000015195A1 (en) * | 1998-09-10 | 2000-03-23 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
| US6375839B1 (en) * | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| US6413419B1 (en) * | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| FR2785196B1 (fr) * | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| JP2002538121A (ja) | 1999-03-03 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | プレニルタンパク質トランスフェラーゼの阻害剤 |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2001027104A1 (en) | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| PT1382339E (pt) | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
| WO2001047922A2 (en) * | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| ATE250924T1 (de) * | 2000-04-07 | 2003-10-15 | Medidom Lab | Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel |
| WO2001081345A1 (en) | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Aromatic amide compounds |
| MXPA02010618A (es) * | 2000-04-25 | 2004-05-05 | Icos Corp | Inhibidores de fosfatidilinositol 3-quinasa delta. |
| US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| IL153115A0 (en) | 2000-06-16 | 2003-06-24 | Curis Inc | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| ATE465756T1 (de) * | 2000-06-23 | 2010-05-15 | Mitsubishi Tanabe Pharma Corp | Antitumoreffekt-verstärker |
| PL359563A1 (pl) * | 2000-06-26 | 2004-08-23 | Pfizer Products Inc. | Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| AU2001278790A1 (en) | 2000-08-22 | 2002-03-04 | Hokuriku Seiyaku Co. Ltd | 1h-imidazopyridine derivatives |
| ATE407132T1 (de) * | 2000-12-05 | 2008-09-15 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| US20040077654A1 (en) * | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| JP2004528295A (ja) | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
| JP4316893B2 (ja) * | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| CA2455181C (en) | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
| US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
| CN101703509A (zh) | 2001-10-30 | 2010-05-12 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| US6949668B2 (en) * | 2001-11-30 | 2005-09-27 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
| PY0228255A (es) | 2001-12-06 | 2004-06-01 | Pfizer Prod Inc | Compuestos cristalinos novedosos |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| JP5466346B2 (ja) | 2002-04-15 | 2014-04-09 | レキット ベンキーザー エルエルシー | グアイフェネシン組合せ剤の徐放 |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| DE60318198T2 (de) | 2002-05-02 | 2008-12-04 | Merck & Co., Inc. | Tyrosinkinase-hemmer |
| MXPA04011004A (es) * | 2002-05-07 | 2005-01-25 | Control Delivery Sys Inc | Procesos para formar un dispositivo de administracion de farmaco. |
| NZ537155A (en) | 2002-05-23 | 2006-09-29 | Cytopia Pty Ltd | Protein kinase inhibitors |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| EP1535934A4 (en) * | 2002-06-26 | 2005-11-02 | Idemitsu Kosan Co | HYDROGENATED COPOLYMER, METHOD FOR THE PRODUCTION THEREOF AND THIS CONTAINING HOTMELT ADHESIVE COMPOSITION |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| EP1541563A4 (en) * | 2002-07-10 | 2007-11-07 | Ono Pharmaceutical Co | ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE |
| JP2006502183A (ja) | 2002-09-20 | 2006-01-19 | アルコン，インコーポレイテッド | ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用 |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| WO2004041814A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
| WO2004047843A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UY28126A1 (es) * | 2002-12-24 | 2004-06-30 | Alcon Inc | Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular |
| TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| US7444183B2 (en) * | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
| CA2515132C (en) * | 2003-02-07 | 2012-01-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrroles useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| US20050043346A1 (en) * | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| DE602004030470D1 (de) * | 2003-10-24 | 2011-01-20 | Santen Pharmaceutical Co Ltd | Therapeutisches mittel für keratokonjunktive erkrankungen |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| CA2545192A1 (en) | 2003-11-25 | 2005-06-09 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
| CA2549485A1 (en) | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| JP4939229B2 (ja) * | 2003-12-19 | 2012-05-23 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール |
| PL1706385T3 (pl) | 2003-12-23 | 2011-03-31 | Astex Therapeutics Ltd | Pochodne pirazolu jako modulatory kinazy białkowej |
| US20050239806A1 (en) * | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| US20050277629A1 (en) | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| NZ584499A (en) | 2004-03-30 | 2011-08-26 | Vertex Pharma | Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| US7558717B2 (en) | 2004-04-28 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Crystal structure of human JAK3 kinase domain complex and binding pockets thereof |
| KR20070006889A (ko) | 2004-05-03 | 2007-01-11 | 노파르티스 아게 | Ｓ1ｐ 수용체 작용제 및 ｊａｋ3 키나제 억제제를 포함하는조합물 |
| WO2005110410A2 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| CN1960988B (zh) | 2004-06-10 | 2012-01-25 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| EP1760071A4 (en) * | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| EP1765819B1 (en) | 2004-06-30 | 2014-03-12 | Vertex Pharmaceuticals Inc. | Azaindoles useful as inhibitors of protein kinases |
| US7138423B2 (en) * | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| WO2006022459A1 (en) | 2004-08-23 | 2006-03-02 | Mogam Biotechnology Institute | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| RU2394826C2 (ru) * | 2004-10-13 | 2010-07-20 | Ф.Хоффманн-Ля Рош Аг | Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| EP1812440B1 (en) | 2004-11-04 | 2010-09-22 | Vertex Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| BRPI0517887A (pt) | 2004-11-24 | 2008-10-21 | Novartis Ag | combinações de inibidores de jaks |
| US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| US20060128803A1 (en) * | 2004-12-14 | 2006-06-15 | Alcon, Inc. | Method of treating dry eye disorders using 13(S)-HODE and its analogs |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
| EP1844037A1 (en) | 2005-01-20 | 2007-10-17 | Pfizer Limited | Chemical compounds |
| RU2434871C2 (ru) * | 2005-02-03 | 2011-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиримидины, применимые в качестве ингибиторов протеинкиназы |
| WO2007044050A2 (en) | 2005-02-04 | 2007-04-19 | Bristol-Myers Squibb Company | 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| MX2007011316A (es) | 2005-03-15 | 2007-11-12 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
| KR20080013886A (ko) | 2005-04-05 | 2008-02-13 | 파마코페이아, 인코포레이티드 | 면역억제용 퓨린 및 이미다조피리딘 유도체 |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| NZ564065A (en) * | 2005-05-20 | 2011-03-31 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AU2006254840B2 (en) | 2005-06-08 | 2012-08-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| PL2395004T3 (pl) | 2005-06-22 | 2016-08-31 | Plexxikon Inc | Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| JP5119154B2 (ja) * | 2005-09-22 | 2013-01-16 | インサイト・コーポレイション | Ｊａｎｕｓキナーゼの四環系阻害剤 |
| EP2532667A1 (en) | 2005-09-30 | 2012-12-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| US20070128633A1 (en) | 2005-10-11 | 2007-06-07 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| DK1937664T3 (da) | 2005-10-14 | 2011-07-18 | Sumitomo Chemical Co | Hydrazidforbindelse og pesticid anvendelse af den samme |
| DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
| NZ567851A (en) * | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| US20130137681A1 (en) * | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
| MX2008008320A (es) * | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Inhibidores de azaindol de aurora cinasas. |
| JP4643455B2 (ja) | 2006-01-12 | 2011-03-02 | 株式会社ユニバーサルエンターテインメント | 遊技システム |
| AR060316A1 (es) | 2006-01-17 | 2008-06-11 | Vertex Pharma | Azaindoles de utilidad como inhibidores de janus quinasas |
| US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| JP2009525350A (ja) | 2006-02-01 | 2009-07-09 | スミスクライン ビーチャム コーポレーション | Ｒａｆキナーゼ阻害薬として有用なピロロ［２，３，ｂ］ピリジン誘導体 |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| RU2008136766A (ru) | 2006-02-24 | 2010-03-27 | Тева Фармасьютикл Индастриес Лтд. (Il) | Таблетки метопролола сукцината пролонгированного действия и способы их приготовления |
| JPWO2007105637A1 (ja) * | 2006-03-10 | 2009-07-30 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| TWI382984B (zh) * | 2006-04-03 | 2013-01-21 | Astellas Pharma Inc | 雜環化合物 |
| CN101460499A (zh) * | 2006-04-05 | 2009-06-17 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的去氮杂嘌呤 |
| WO2007116313A2 (en) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| EP2040704A2 (en) | 2006-05-18 | 2009-04-01 | Bayer Healthcare Ag | Pharmaceutical compositions comprising implitapide and methods of using same |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| NZ573174A (en) | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| WO2008011557A2 (en) * | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| ATE517868T1 (de) * | 2006-08-16 | 2011-08-15 | Boehringer Ingelheim Int | Pyrazinverbindungen, ihre verwendung und herstellungsverfahren |
| AU2007293653B2 (en) | 2006-09-08 | 2011-02-17 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| AR063141A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| WO2008058126A2 (en) * | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| KR101532256B1 (ko) | 2006-11-22 | 2015-06-29 | 인사이트 코포레이션 | 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘 |
| WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| CN101562977A (zh) * | 2006-12-15 | 2009-10-21 | 艾博特公司 | 新的二唑化合物 |
| US8338455B2 (en) * | 2006-12-20 | 2012-12-25 | Amgen Inc. | Compounds and methods of use |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| ES2431163T3 (es) | 2007-03-01 | 2013-11-25 | Novartis Ag | Inhibidores de PIM quinasa y métodos para su uso |
| WO2008124323A1 (en) | 2007-04-03 | 2008-10-16 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| US8188178B2 (en) | 2007-05-07 | 2012-05-29 | 3M Innovative Properties Company | Cold shrinkable article including an epichlorohydrin composition |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| WO2009007839A1 (en) | 2007-07-11 | 2009-01-15 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| CN101815712A (zh) * | 2007-08-01 | 2010-08-25 | 辉瑞有限公司 | 吡唑化合物及其作为raf抑制剂的用途 |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| ES2569528T3 (es) | 2007-11-16 | 2016-05-11 | Incyte Holdings Corporation | 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| PL3133080T3 (pl) * | 2008-01-18 | 2018-12-31 | Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nowe cytostatyczne nukleozydy 7-deazapurynowe |
| CN101959404B (zh) | 2008-02-04 | 2015-12-02 | 墨丘瑞医疗有限公司 | 单磷酸腺苷活化蛋白激酶调节剂 |
| UY31679A1 (es) | 2008-03-03 | 2009-09-30 | Inhibidores de cinasa pim y metodos para su uso | |
| PL2288610T3 (pl) | 2008-03-11 | 2017-12-29 | Incyte Holdings Corporation | Azetydynowe i cyklobutanowe pochodne jako inhibitory jak |
| EA201001456A1 (ru) | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
| US8344144B2 (en) | 2008-06-18 | 2013-01-01 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| US20110212157A1 (en) | 2008-06-26 | 2011-09-01 | Anterios, Inc. | Dermal delivery |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| EP2384326B1 (en) | 2008-08-20 | 2014-04-23 | Zoetis LLC | Pyrrolo[2,3-d]pyrimidine compounds |
| CN104311480A (zh) | 2008-09-02 | 2015-01-28 | 诺华股份有限公司 | 作为激酶抑制剂的吡啶甲酰胺衍生物 |
| CA2735782A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Heterocyclic pim-kinase inhibitors |
| BRPI0918496A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| EP2350054A4 (en) | 2008-10-17 | 2012-03-28 | Merck Canada Inc | AZETIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE |
| TWI665200B (zh) * | 2009-01-15 | 2019-07-11 | 英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| EP3643312A1 (en) * | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| EP2451813B1 (en) | 2009-07-08 | 2014-10-01 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| EP2470534A4 (en) | 2009-08-24 | 2013-02-27 | Merck Sharp & Dohme | JAK INHIBITION FOR BLOCKING TOXICITY ASSOCIATED WITH RNA INTERFERENCE |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| SG10201405568UA (en) | 2009-09-08 | 2014-11-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| CN105541847B (zh) | 2009-10-09 | 2019-08-16 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
| AU2010309882B2 (en) | 2009-10-20 | 2016-01-28 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors |
| US8671402B2 (en) | 2009-11-09 | 2014-03-11 | Bank Of America Corporation | Network-enhanced control of software updates received via removable computer-readable medium |
| EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| EP2506852A4 (en) | 2009-12-04 | 2013-06-19 | Univ Texas | INTERFERONTHERAPIES IN COMBINATION WITH BLOCKING OF STAT3 ACTIVATION |
| WO2011075334A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| US8461328B2 (en) | 2010-01-12 | 2013-06-11 | Genentech, Inc. | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| WO2011097087A1 (en) | 2010-02-05 | 2011-08-11 | Pfizer Inc. | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| CN102844317B (zh) * | 2010-02-18 | 2015-06-03 | 因西特公司 | 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物 |
| EP3050882B1 (en) | 2010-03-10 | 2018-01-31 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PH12012502046A1 (en) | 2010-04-14 | 2017-07-26 | Array Biopharma Inc | 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| SG10201503983QA (en) | 2010-05-21 | 2015-06-29 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
| US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
| US9351943B2 (en) | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
| WO2012045020A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| US9034884B2 (en) * | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| CA2819560A1 (en) | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
| ES2547916T3 (es) * | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| CN102247368B (zh) | 2011-05-19 | 2013-05-29 | 安徽永生堂药业有限责任公司 | 一种复方阿伐斯汀缓释片及其制备方法 |
| CN102218042A (zh) | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| HK1198579A1 (en) | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| TW201313721A (zh) * | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| ES2867048T3 (es) | 2012-06-15 | 2021-10-20 | Concert Pharmaceuticals Inc | Derivados deuterados de ruxolitinib |
| CA2879603A1 (en) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| CN102772384A (zh) | 2012-08-07 | 2012-11-14 | 四川百利药业有限责任公司 | 一种盐酸米诺环素缓释片及其制备方法 |
| US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| AU2013337824B2 (en) | 2012-11-01 | 2018-03-08 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| PL2919766T3 (pl) | 2012-11-15 | 2021-10-04 | Incyte Holdings Corporation | Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu |
| CN105189509B (zh) | 2013-03-06 | 2017-12-19 | 因赛特公司 | 用于制备jak抑制剂的方法及中间体 |
| SMT202100040T1 (it) | 2013-05-17 | 2021-03-15 | Incyte Corp | Derivati di bipirazolo come inibitori di jak |
| SG10201912203XA (en) | 2013-08-07 | 2020-02-27 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| EP3035966A1 (en) | 2013-08-20 | 2016-06-29 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| CA2940659C (en) | 2014-02-28 | 2023-01-03 | Incyte Corporation | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| KR20240153401A (ko) | 2014-04-08 | 2024-10-22 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료 |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| US10363260B2 (en) | 2014-05-28 | 2019-07-30 | Oncotracker, Inc. | Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| CN113906032A (zh) | 2019-02-06 | 2022-01-07 | 康塞特医药品有限公司 | 用于制备对映异构体富集的jak抑制剂的方法 |
-
2006
- 2006-12-12 TW TW105120803A patent/TWI630207B/zh active
- 2006-12-12 SG SG10202003901UA patent/SG10202003901UA/en unknown
- 2006-12-12 TW TW095146502A patent/TWI410407B/zh active
- 2006-12-12 EP EP11152714.9A patent/EP2474545B1/en active Active
- 2006-12-12 WO PCT/US2006/047369 patent/WO2007070514A1/en not_active Ceased
- 2006-12-12 MY MYPI2013002970A patent/MY162590A/en unknown
- 2006-12-12 MY MYPI20082099A patent/MY159449A/en unknown
- 2006-12-12 HU HUE16197502A patent/HUE041382T2/hu unknown
- 2006-12-12 DK DK11152677.8T patent/DK2343299T3/en active
- 2006-12-12 TW TW107113620A patent/TWI664182B/zh active
- 2006-12-12 ES ES18191992T patent/ES2867505T3/es active Active
- 2006-12-12 NZ NZ569015A patent/NZ569015A/en unknown
- 2006-12-12 PL PL06839328T patent/PL1966202T3/pl unknown
- 2006-12-12 LT LTEP11152730.5T patent/LT2455382T/lt unknown
- 2006-12-12 ES ES06839328T patent/ES2373688T3/es active Active
- 2006-12-12 CN CNA2006800527507A patent/CN101448826A/zh not_active Withdrawn
- 2006-12-12 SI SI200632137A patent/SI2474545T1/sl unknown
- 2006-12-12 PL PL11152677.8T patent/PL2343299T3/pl unknown
- 2006-12-12 EA EA201200132A patent/EA035795B1/ru active Protection Beyond IP Right Term
- 2006-12-12 EP EP11152674.5A patent/EP2343298B9/en active Active
- 2006-12-12 SI SI200632020A patent/SI2343299T1/sl unknown
- 2006-12-12 HU HUE11152677A patent/HUE028588T2/hu unknown
- 2006-12-12 KR KR1020127024523A patent/KR101324737B1/ko active Active
- 2006-12-12 JP JP2008545733A patent/JP5017278B2/ja active Active
- 2006-12-12 SI SI200632135A patent/SI2426129T1/sl unknown
- 2006-12-12 SI SI200632133A patent/SI2455382T1/sl unknown
- 2006-12-12 AU AU2006326548A patent/AU2006326548B2/en active Active
- 2006-12-12 ES ES11152708.1T patent/ES2543904T3/es active Active
- 2006-12-12 DK DK11152723.0T patent/DK2426129T3/en active
- 2006-12-12 PT PT111526778T patent/PT2343299E/pt unknown
- 2006-12-12 AT AT06839328T patent/ATE525374T1/de active
- 2006-12-12 HU HUE11152723A patent/HUE030235T2/en unknown
- 2006-12-12 PL PL16197502T patent/PL3184526T3/pl unknown
- 2006-12-12 PL PL11152714T patent/PL2474545T3/pl unknown
- 2006-12-12 EA EA200870048A patent/EA019504B1/ru active Protection Beyond IP Right Term
- 2006-12-12 HR HR20110903T patent/HRP20110903T1/hr unknown
- 2006-12-12 CA CA2632466A patent/CA2632466C/en active Active
- 2006-12-12 PL PL11152723T patent/PL2426129T3/pl unknown
- 2006-12-12 RS RS20170079A patent/RS55632B1/sr unknown
- 2006-12-12 RS RS20181405A patent/RS58113B1/sr unknown
- 2006-12-12 CN CN201310058991.4A patent/CN103254190B/zh active Active
- 2006-12-12 PT PT16197502T patent/PT3184526T/pt unknown
- 2006-12-12 LT LTEP11152714.9T patent/LT2474545T/lt unknown
- 2006-12-12 EP EP11152677.8A patent/EP2343299B9/en active Active
- 2006-12-12 CN CN201310058988.2A patent/CN103214483B/zh active Active
- 2006-12-12 ES ES20206996T patent/ES2970354T3/es active Active
- 2006-12-12 PT PT111527230T patent/PT2426129T/pt unknown
- 2006-12-12 LT LTEP16197502.4T patent/LT3184526T/lt unknown
- 2006-12-12 RS RS20170047A patent/RS55576B1/sr unknown
- 2006-12-12 EP EP20206996.9A patent/EP3838903B1/en active Active
- 2006-12-12 RS RS20110571A patent/RS52101B/sr unknown
- 2006-12-12 ES ES11152677.8T patent/ES2561507T3/es active Active
- 2006-12-12 EP EP16197502.4A patent/EP3184526B1/en active Active
- 2006-12-12 ME MEP-2011-199A patent/ME01312B/me unknown
- 2006-12-12 PT PT06839328T patent/PT1966202E/pt unknown
- 2006-12-12 EP EP06839328A patent/EP1966202B1/en active Active
- 2006-12-12 HU HUE11152714A patent/HUE032337T2/en unknown
- 2006-12-12 KR KR1020127024525A patent/KR101391900B1/ko active Active
- 2006-12-12 SG SG2012014957A patent/SG179430A1/en unknown
- 2006-12-12 ES ES11152714.9T patent/ES2612489T3/es active Active
- 2006-12-12 RS RS20160052A patent/RS54683B1/sr unknown
- 2006-12-12 RS RS20150513A patent/RS54181B9/sr unknown
- 2006-12-12 BR BRPI0619817A patent/BRPI0619817B8/pt active IP Right Grant
- 2006-12-12 SG SG10201506912RA patent/SG10201506912RA/en unknown
- 2006-12-12 ES ES11152674.5T patent/ES2543903T3/es active Active
- 2006-12-12 DK DK11152730.5T patent/DK2455382T3/da active
- 2006-12-12 DK DK06839328.9T patent/DK1966202T3/da active
- 2006-12-12 HU HUE11152708A patent/HUE025173T2/hu unknown
- 2006-12-12 PT PT111527305T patent/PT2455382T/pt unknown
- 2006-12-12 UA UAA201115478A patent/UA116187C2/uk unknown
- 2006-12-12 PT PT111527149T patent/PT2474545T/pt unknown
- 2006-12-12 PT PT111527081T patent/PT2348023E/pt unknown
- 2006-12-12 TW TW103117669A patent/TW201434835A/zh unknown
- 2006-12-12 EP EP18191992.9A patent/EP3466953B1/en active Active
- 2006-12-12 SI SI200631209T patent/SI1966202T1/sl unknown
- 2006-12-12 SI SI200631956T patent/SI2348023T1/sl unknown
- 2006-12-12 NZ NZ778831A patent/NZ778831A/en unknown
- 2006-12-12 DK DK11152714.9T patent/DK2474545T3/en active
- 2006-12-12 ES ES11152723.0T patent/ES2612196T3/es active Active
- 2006-12-12 PL PL11152708T patent/PL2348023T3/pl unknown
- 2006-12-12 EA EA201691294A patent/EA036785B1/ru active Protection Beyond IP Right Term
- 2006-12-12 RS RS20170081A patent/RS55634B1/sr unknown
- 2006-12-12 ES ES11152730.5T patent/ES2611588T3/es active Active
- 2006-12-12 EP EP11152708.1A patent/EP2348023B9/en active Active
- 2006-12-12 TW TW103136068A patent/TWI553008B/zh active
- 2006-12-12 US US11/637,545 patent/US7598257B2/en active Active
- 2006-12-12 TW TW101121442A patent/TWI468162B/zh active
- 2006-12-12 MX MX2015003466A patent/MX346183B/es unknown
- 2006-12-12 HU HUE11152730A patent/HUE030418T2/en unknown
- 2006-12-12 UA UAA200809072A patent/UA98449C2/ru unknown
- 2006-12-12 ES ES16197502T patent/ES2700433T3/es active Active
- 2006-12-12 SI SI200632294T patent/SI3184526T1/sl unknown
- 2006-12-12 EP EP11152730.5A patent/EP2455382B1/en active Active
- 2006-12-12 CN CN201310059187.8A patent/CN103214484B/zh active Active
- 2006-12-12 DK DK11152708.1T patent/DK2348023T5/da active
- 2006-12-12 PL PL11152730T patent/PL2455382T3/pl unknown
- 2006-12-12 EP EP11152723.0A patent/EP2426129B1/en active Active
- 2006-12-12 KR KR1020117029741A patent/KR101218214B1/ko active Active
- 2006-12-12 LT LTEP11152723.0T patent/LT2426129T/lt unknown
- 2006-12-12 DK DK16197502.4T patent/DK3184526T3/en active
- 2006-12-13 AR ARP060105499A patent/AR057995A1/es active IP Right Grant
-
2008
- 2008-06-05 IL IL192019A patent/IL192019A/en active IP Right Grant
- 2008-06-12 ZA ZA2008/05165A patent/ZA200805165B/en unknown
- 2008-06-12 CR CR10065A patent/CR10065A/es unknown
- 2008-06-12 US US12/138,082 patent/US8415362B2/en active Active
- 2008-06-13 EC EC2008008540A patent/ECSP088540A/es unknown
- 2008-07-11 KR KR1020087017011A patent/KR101216055B1/ko active Active
-
2009
- 2009-08-27 US US12/549,170 patent/US8541425B2/en active Active
-
2011
- 2011-03-30 US US13/076,220 patent/US8530485B2/en active Active
- 2011-03-30 US US13/076,176 patent/US8946245B2/en active Active
- 2011-09-05 JP JP2011192962A patent/JP5710430B2/ja active Active
- 2011-12-20 CY CY20111101270T patent/CY1112762T1/el unknown
-
2012
- 2012-03-08 EC ECSP12008540 patent/ECSP12008540A/es unknown
-
2013
- 2013-01-09 LT LTPA2013002C patent/LTPA2013002I1/lt unknown
- 2013-01-18 LU LU92137C patent/LU92137I2/fr unknown
- 2013-01-21 FR FR13C0007C patent/FR13C0007I2/fr active Active
- 2013-02-15 CY CY2013006C patent/CY2013006I1/el unknown
- 2013-02-19 BE BE2013C014C patent/BE2013C014I2/fr unknown
- 2013-09-06 US US14/020,505 patent/US9206187B2/en active Active
- 2013-09-20 US US14/033,039 patent/US8933086B2/en active Active
- 2013-10-03 CR CR20130506A patent/CR20130506A/es unknown
- 2013-12-17 JP JP2013260480A patent/JP5876026B2/ja active Active
-
2014
- 2014-04-08 IL IL231992A patent/IL231992A/en active IP Right Grant
- 2014-05-12 US US14/274,948 patent/US9079912B2/en active Active
-
2015
- 2015-05-13 US US14/711,576 patent/US20150238492A1/en not_active Abandoned
- 2015-07-06 JP JP2015135307A patent/JP6138865B2/ja active Active
- 2015-07-31 CY CY20151100673T patent/CY1116574T1/el unknown
- 2015-08-06 HR HRP20150837TT patent/HRP20150837T2/hr unknown
-
2016
- 2016-02-02 HR HRP20160112TT patent/HRP20160112T1/hr unknown
- 2016-06-03 US US15/173,057 patent/US9662335B2/en active Active
- 2016-08-10 US US15/233,652 patent/US9814722B2/en active Active
- 2016-11-13 IL IL248938A patent/IL248938A0/en unknown
- 2016-11-21 US US15/356,957 patent/US9974790B2/en active Active
-
2017
- 2017-01-19 HR HRP20170090TT patent/HRP20170090T1/hr unknown
- 2017-01-20 CY CY20171100089T patent/CY1118506T1/el unknown
- 2017-01-30 CY CY20171100130T patent/CY1118724T1/el unknown
- 2017-02-01 HR HRP20170162TT patent/HRP20170162T1/hr unknown
- 2017-02-07 HR HRP20170200TT patent/HRP20170200T1/hr unknown
- 2017-02-08 CY CY20171100171T patent/CY1118607T1/el unknown
- 2017-04-25 LT LTPA2017012C patent/LTPA2017012I1/lt unknown
- 2017-04-25 FR FR17C1013C patent/FR17C1013I2/fr active Active
- 2017-04-25 CY CY2017015C patent/CY2017015I1/el unknown
- 2017-04-25 HU HUS1700017C patent/HUS1700017I1/hu unknown
-
2018
- 2018-04-23 US US15/960,069 patent/US10398699B2/en active Active
- 2018-11-01 US US16/177,602 patent/US10639310B2/en active Active
- 2018-11-16 HR HRP20181912TT patent/HRP20181912T1/hr unknown
- 2018-12-27 CY CY20181101401T patent/CY1121202T1/el unknown
-
2020
- 2020-03-17 US US16/821,624 patent/US11331320B2/en active Active
-
2022
- 2022-03-08 US US17/689,510 patent/US11744832B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| TWI553008B (zh) * | 2005-12-13 | 2016-10-11 | 英塞特控股公司 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并[2,3-b]吡啶及吡咯并[2,3-b]嘧啶 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI630207B (zh) | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 | |
| HK1160115B (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
| HK1160137B (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |